Trends of measles in Tanzania: A 5-year review of case-based surveillance data, 2018-2022
Vaccines provide a safe and cost-effective solution to vaccine-preventable infectious diseases. However, vaccine-preventable infectious diseases still pose a serious public health threat, especially in the world's poor regions [1]. In sub-Saharan Africa, this burden is further aggravated by the occurrence of concurrent epidemics such as COVID-19, Ebola virus disease, monkeypox, and measles overstretching the already weak public health system [2]. In addition to human conflicts, natural disasters, and vaccine hesitancy, the COVID-19 pandemic has disrupted routine immunization services leaving millions of children under-vacc...
Source: International Journal of Infectious Diseases - December 17, 2023 Category: Infectious Diseases Authors: Fausta Michael, Mariam M. Mirambo, Gerald Misinzo, Omary Minzi, Medard Beyanga, Delphinus Mujuni, Florence S. Kalabamu, Elias N. Nyanda, Mary Mwanyika-Sando, Daniel Ndiyo, Richard Kasonogo, Abbas Ismail, Andrew Bahati, Farida Hassan, Eliangiringa Kaale, J Source Type: research
Policy responses to the COVID-19 pandemic in West Africa: a scoping review protocol
The objective of this scoping review is to understand the extent and type of evidence in relation to the policy formulation, decision-making and implementation stages of NPIs in West Africa.
Methods and analysis
A scoping review will be undertaken following the guidance developed by Arskey and O’Malley, the Joanna Briggs Institute (JBI) methodology for scoping reviews and the PRISMA guidelines for Scoping Reviews. Both peer-reviewed and grey literature will be searched using Web of Science, Embase, Scopus, APA PsycInfo, WHO Institutional Repository for Information Sharing, JSTOR and Google Advanced Search, and by se...
Source: BMJ Open - December 10, 2023 Category: General Medicine Authors: Fischer, H.-T., Müller, K., Wenham, C., Hanefeld, J. Tags: Open access, Global health, COVID-19 Source Type: research
Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned
Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.11.030. Online ahead of print.ABSTRACTConducting a vaccine trial in a low- and middle-income country (LMIC) can present unique challenges and lessons learned. This Ebola vaccine trial, enrolling 699 healthcare providers and frontliners and jointly set up by the University of Antwerp (Sponsor) and the University of Kinshasa (Principal Investigator (PI)), was conducted in Boende, a remote city in the Democratic Republic of the Congo (DRC), between December 2019 and October 2022 (ClinicalTrials.gov: NCT04186000). While being bound by strict ICH-GCP and in...
Source: Vaccine - November 22, 2023 Category: Allergy & Immunology Authors: Ynke Larivi ère Tr ésor Zola Matuvanga Gwen Lemey Bernard Isekah Osang'ir Paul Peter Vermeiren Solange Milolo Rachel Meta Primo Kimbulu Emmanuel Esanga Junior Matangila Jean-Pierre Van Geertruyden Pierre Van Damme Vivi Maketa Hypolite Muhindo-Mavoko Pat Source Type: research
Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned
Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.11.030. Online ahead of print.ABSTRACTConducting a vaccine trial in a low- and middle-income country (LMIC) can present unique challenges and lessons learned. This Ebola vaccine trial, enrolling 699 healthcare providers and frontliners and jointly set up by the University of Antwerp (Sponsor) and the University of Kinshasa (Principal Investigator (PI)), was conducted in Boende, a remote city in the Democratic Republic of the Congo (DRC), between December 2019 and October 2022 (ClinicalTrials.gov: NCT04186000). While being bound by strict ICH-GCP and in...
Source: Vaccine - November 22, 2023 Category: Allergy & Immunology Authors: Ynke Larivi ère Tr ésor Zola Matuvanga Gwen Lemey Bernard Isekah Osang'ir Paul Peter Vermeiren Solange Milolo Rachel Meta Primo Kimbulu Emmanuel Esanga Junior Matangila Jean-Pierre Van Geertruyden Pierre Van Damme Vivi Maketa Hypolite Muhindo-Mavoko Pat Source Type: research
A premature newborn born to an adolescent girl with acute Ebola virus disease and malaria survives in a resource ‐limited setting in an Ebola treatment unit in DR Congo: “A case report”
Key Clinical MessageIn the acute phase of Ebola virus disease (EVD) premature neonatal survival is extremely rare. High mortality is related to prematurity, neonatal complications of Ebola, and precarious conditions of neonatal care in underresourced ETUs. This is a case of preterm neonatal survival in the setting of acute maternal EVD infection.AbstractThis case describes rare preterm newborn survival in the setting of an Ebola treatment unit in Eastern DRC. The neonate was born vaginally to an acutely ill 17-year-old mother who was vaccinated against Ebola virus after being identified as a contact of her father, who was ...
Source: Clinical Case Reports - November 22, 2023 Category: General Medicine Authors: Prince Imani ‐Musimwa,
Emilie Grant,
Micheline Feza‐Malira,
Placide Mbala‐Kingebeni,
Gisèle Buhoro‐Baabo,
Espérence Zawadi‐Endanda,
Rigo Fraterne‐Muhayangabo,
Inès Claris‐Mwatsi,
Zacharie Tsongo‐Kibendelwa,
Olivier Nyakio‐Nge Tags: CASE REPORT Source Type: research
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Biotechnol Adv. 2023 Nov 14:108283. doi: 10.1016/j.biotechadv.2023.108283. Online ahead of print.ABSTRACTA key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies targeting viral attachment and fusion glycoproteins that embellish viral particles. This observation has catalyzed the development of numerous viral glycoprotein mimetics as vaccines. Glycans can dominate the surface of viral glycoproteins and as such, the viral glycome can influence the antigenicity and immunogenicity of a candidate vaccine. In one extreme, glycans can form an integral part of epitopes targeted by neutralizing...
Source: Biotechnology Advances - November 16, 2023 Category: Biotechnology Authors: M L Newby J D Allen M Crispin Source Type: research
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Biotechnol Adv. 2023 Nov 14:108283. doi: 10.1016/j.biotechadv.2023.108283. Online ahead of print.ABSTRACTA key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies targeting viral attachment and fusion glycoproteins that embellish viral particles. This observation has catalyzed the development of numerous viral glycoprotein mimetics as vaccines. Glycans can dominate the surface of viral glycoproteins and as such, the viral glycome can influence the antigenicity and immunogenicity of a candidate vaccine. In one extreme, glycans can form an integral part of epitopes targeted by neutralizing...
Source: Biotechnology Advances - November 16, 2023 Category: Biotechnology Authors: M L Newby J D Allen M Crispin Source Type: research
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Biotechnol Adv. 2023 Nov 14;70:108283. doi: 10.1016/j.biotechadv.2023.108283. Online ahead of print.ABSTRACTA key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies targeting viral attachment and fusion glycoproteins that embellish viral particles. This observation has catalyzed the development of numerous viral glycoprotein mimetics as vaccines. Glycans can dominate the surface of viral glycoproteins and as such, the viral glycome can influence the antigenicity and immunogenicity of a candidate vaccine. In one extreme, glycans can form an integral part of epitopes targeted by neutraliz...
Source: Biotechnology Advances - November 16, 2023 Category: Biotechnology Authors: Maddy L Newby Joel D Allen Max Crispin Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
